Literature DB >> 16254404

Restricted diffusion of the splenium in acute Wernicke's encephalopathy.

Yince Loh1, William D Watson, Ajay Verma, Pavel Krapiva.   

Abstract

Acute Wernicke's encephalopathy (WE) is caused by profound vitamin B1 (thiamine) deficiency and commonly presents with the classic clinical triad of mental confusion, ataxia, and ophthalmoplegia. This characteristic presentation results from the propensity of acute thiamine deficiency to preferentially injure specific brain regions: the dorsomedial thalamus, periaqueductal gray, and mamillary bodies. In these regions, abnormal magnetic resonance signaling on conventional sequences has been well described; however, diffusion restriction has only recently been reported. The authors demonstrate diffusion-weighted imaging (DWI) abnormalities of the splenium of the corpus callosum in a patient with acute WE, which has not been reported previously, and suggest a potential pathological mechanism. With the recent addition of DWI, MRI is becoming more sensitive to the changes in acute WE. Furthermore, the use of apparent diffusion coefficient mapping to evaluate the extent of likely underlying cytotoxic injury may help determine long-term response to vitamin therapy and, thus, disability.

Entities:  

Mesh:

Year:  2005        PMID: 16254404     DOI: 10.1177/1051228405279037

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  11 in total

1.  Spectrum of MR imaging findings in Wernicke encephalopathy: are atypical areas of involvement only present in nonalcoholic patients?

Authors:  N D Ha; Y C Weon; J C Jang; B S Kang; S H Choi
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

Review 2.  [Corpus callosum. Landmark of the origin of cerebral diseases].

Authors:  E Hattingen; M Nichtweiss; S Blasel; F E Zanella; S Weidauer
Journal:  Radiologe       Date:  2010-02       Impact factor: 0.635

Review 3.  CT and MRI of Wernicke's encephalopathy.

Authors:  A Cerase; E Rubenni; A Rufa; I Vallone; P Galluzzi; G Coratti; F Franchi; F Giannini; C Venturi
Journal:  Radiol Med       Date:  2011-01-12       Impact factor: 3.469

4.  Reversible splenial abnormality in hypoglycemic encephalopathy.

Authors:  Ji Hyun Kim; Jeong Yoon Choi; Seong-Beom Koh; Younghen Lee
Journal:  Neuroradiology       Date:  2006-11-30       Impact factor: 2.804

Review 5.  Reversible focal splenial lesions.

Authors:  Massimo Gallucci; Nicola Limbucci; Amalia Paonessa; Ferdinando Caranci
Journal:  Neuroradiology       Date:  2007-05-24       Impact factor: 2.804

Review 6.  Diagnosis and management of Marchiafava-Bignami disease: a review of CT/MRI confirmed cases.

Authors:  Matti Hillbom; Pertti Saloheimo; Shinsuke Fujioka; Zbigniew K Wszolek; Seppo Juvela; Maurizio A Leone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-08-26       Impact factor: 10.154

7.  Clinical characteristics and magnetic resonance imaging findings in nine patients with nonalcoholic Wernicke's encephalopathy: a retrospective study.

Authors:  Yong-Lin Liu; Wei-Min Xiao; Man-Qiu Liang; Zhi-Qiang Wu; Ya-Zhi Wang; Jian-Feng Qu; Yang-Kun Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-26       Impact factor: 2.570

8.  A Case of Cortical Involvement in Marchiafava-Bignami Disease Accompanying Wernicke's Encephalopathy.

Authors:  Michelle Youn; Jung Ju Lee; Jong Moo Park; Kyusik Kang; Ohyun Kwon; Woong Woo Lee; Byung Kun Kim
Journal:  J Clin Neurol       Date:  2021-07       Impact factor: 3.077

Review 9.  MR imaging findings in alcoholic and nonalcoholic acute Wernicke's encephalopathy: a review.

Authors:  Gaetana Manzo; Angela De Gennaro; Attilio Cozzolino; Antonietta Serino; Giacomo Fenza; Andrea Manto
Journal:  Biomed Res Int       Date:  2014-06-24       Impact factor: 3.411

Review 10.  The splenium of the corpus callosum: embryology, anatomy, function and imaging with pathophysiological hypothesis.

Authors:  J Blaauw; L C Meiners
Journal:  Neuroradiology       Date:  2020-02-15       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.